Portfolio News

 

   
December 2013
CSA Medical
SV Life Sciences Fund V invested in CSA Medical, the leading developer of novel Spray Cryotherapy devices that freeze and destroy unwanted tissue inside the body, as part of a $16m financing round. ...

Read more

Team - Paul LaViolette, David Milne
December 2013
Rempex Pharmacuticals Exit
SV Life Sciences notes that on 04 December 2013 – The Medicines Company (NASDAQ: MDCO) entered in to a definitive agreement to purchase Rempex Pharmaceuticals for an upfront payment price of $140m and has agreed to pay Rempex equity holders milestone payments subsequent to closing. ...

Read more

Team - Michael Ross
November 2013
Sutro Biopharma
SV Life Science Fund V invested in Sutro Biopharma, an on-going development of low cost, high quality rapidly developed protein pharmaceuticals and innovative vaccines, as part of a $26m series D financing round.  ...

Read more

Team - Michael Ross
November 2013
Juvaris - Investment
SV Life Sciences Fund IV invested in Juvaris, developing adjuvanted vaccines for infectious diseases as part of a $300k bridge loan financing round.  ...

Read more

Team - Bruce A Peacock, Michael Ross
November 2013
TopiVert Investment
SV Life Sciences notes that SV Life Science Fund V invested in TopiVert, focused on developing topical medicines for inflammatory diseases of the eye and gut as part of a £1m bridge funding round.   ...

Read more

Team - Kate Bingham, Graham Boulnois, Hamish Cameron, Michael Carter
November 2013
Cibiem Investment
SV Life Sciences notes that SV Life Science Fund V invested in Cibiem Inc. formerly Coridea NC1. Developer of CBM (Carotid Body Modulation) treatment of sympathetic nervous system-mediated diseases such as hypertension, heat failure, diabetes and renal failure as part of a $13m series B financing round. ...

Read more

Team - Paul LaViolette, David Milne
October 29, 2013
Delenex Therapeutics
SV Life Sciences Advisers notes that Delenex Therapeutics closes CHF 7.3 (USD 8.0) Million Series A3 Financing.   Delenex Therapeutics AG, a biotechnology company developing topical and local treatments for dermatologic diseases using its proprietary PENTRA bodies, today announced the closing of a CHF 7.3 (USD 8.0) Million Series A3 round. All existing venture investors, HBM Ventures, Novo A/s, SV Life Sciences, BioMedinvest and Venture Incubator participated in the round.

Read more

Team - Kate Bingham, Graham Boulnois
September 24, 2013
Ophthotech- IPO
SV Life Sciences Advisers notes that Ophthotech successfully listed on NASDAQ on 25 September 2013 NEW YORK, Sep 24, 2013 (BUSINESS WIRE) -- Ophthotech Corporation today announced the pricing of its initial public offering of 7,600,000 shares of common stock at a public offering price of $22.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Ophthotech.

Read more

Team - David Guyer, Michael Ross
September 4, 2013
Transenterix merger with SafeStitch Medical (OTCBB: SFES)
SV Life Sciences Advisers notes that TransEnterix successfully merged with SafeStitch Medical on 4 September 2013. $30 Million Financing Raised from Existing TransEnterix and SafeStitch Medical Stockholders Combined Company to be Renamed TransEnterix MIAMI & RESEARCH TRIANGLE, N.C.--(BUSINESS WIRE)--September 04, 2013 SafeStitch Medical, Inc. (OTCBB: SFES) and TransEnterix, Inc.

Read more

Team - Paul LaViolette, David Milne
May 2013
Maestro Healthcare Technology Investment
SV Life Sciences Advisers notes that SV Life Science Fund V invested in Maestro Healthcare, Technology-enabled healthcare service company that sells defined contribution plans to employers via private exchange as part of a $1m financing round. ...

Read more

Team - Tom Flynn, Eugene Hill
May 2013
Bicycle Therapeutics Investment
SV Life Sciences Advisers notes that SV Life Science Fund V invested in Bicycle Therapeutics, developing a platform technology that may enable the creation of a new generation of bio therapeutics as part of a £7.7m series A financing round.  ...

Read more

Team - Kate Bingham, Graham Boulnois, Hamish Cameron, Michael Carter
May 2013
Autifony Therapeutics Investment
SV Life Sciences Advisers notes that SV Life Science Fund V invested in Maestro Healthcare, Technology-enabled healthcare service company that sells defined contribution plans to employers via private exchange as part of a $1m financing round. ...

Read more

Team - Tom Flynn, Eugene Hill
April 2013
WellNow Urgent Care Investment
SV Life Sciences Advisers notes that SV Life Science Fund V invested in WellNow Urgent Care, an urgent care company focused on treating patients. Clinics offer you the convenience and expertise to treat everything that is non-life or limb threatening illness or injury as part of a $25m series A financing round. ...

Read more

Team - Tom Flynn, Eugene Hill
March 2013
Neurotech - Investment
SV Life Sciences Fund III invested in Neurotech, developer of an encapsulated cell therapy for the delivery of therapeutic proteins in retinal diseases, as part of a $3m bridge loan financing round.  ...

Read more

Team - David Guyer, Michael Ross

⇧ Back to top